E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Synthesis of Marine-Derived Compounds"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 April 2018

Special Issue Editor

Guest Editor
Assoc. Prof. Dr. Lyndon West

Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, FL 33431, USA
Website | E-Mail
Interests: marine natural products; drug discovery; biomimetic synthesis; NMR

Special Issue Information

Dear Colleagues,

The chemical complexity and diverse biological activities of marine natural products have been a source of inspiration, and the challenge of mimicking distinctive three-dimensional structures presents unique research opportunities that push the boundaries of organic chemistry. Natural Product synthesis, both total and partial (semi-synthesis), provides the confirmation of structure, allows the ability to carry-out structure–activity relationship (SAR) studies, lead optimization, together with providing a potential solution to the supply issue that has curtailed the development of many marine natural products. The aim of this Special Issue is to highlight the chemical and biological discoveries resulting from the total synthesis or semi-synthesis of marine-derived natural products. As the Guest Editor, I invite scientists in the fields of chemistry, biochemistry, pharmacology, and toxicology to submit review papers or original articles where synthesis has contributed to the field of marine natural products drug discovery.

Assoc. Prof. Dr. Lyndon West
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine natural product
  • Total synthesis
  • Biomimetic synthesis
  • Semi-synthesis
  • Chemical transformation
  • Structure-activity relationship
  • Lead optimization
  • Pharmacology

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Discovery of Novel Bromophenol Hybrids as Potential Anticancer Agents through the Ros-Mediated Apoptotic Pathway: Design, Synthesis and Biological Evaluation
Mar. Drugs 2017, 15(11), 343; doi:10.3390/md15110343
Received: 23 September 2017 / Revised: 18 October 2017 / Accepted: 30 October 2017 / Published: 1 November 2017
PDF Full-text (4119 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
A series of bromophenol hybrids with N-containing heterocyclic moieties were designed, and their anticancer activities against a panel of five human cancer cell lines (A549, Bel7402, HepG2, HCT116 and Caco2) using MTT assay in vitro were explored. Among them, thirteen compounds (17a
[...] Read more.
A series of bromophenol hybrids with N-containing heterocyclic moieties were designed, and their anticancer activities against a panel of five human cancer cell lines (A549, Bel7402, HepG2, HCT116 and Caco2) using MTT assay in vitro were explored. Among them, thirteen compounds (17a, 17b, 18a, 19a, 19b, 20a, 20b, 21a, 21b, 22a, 22b, 23a, and 23b) exhibited significant inhibitory activity against the tested cancer cell lines. The structure-activity relationships (SARs) of bromophenol derivatives were discussed. The promising candidate compound 17a could induce cell cycle arrest at G0/G1 phase and induce apoptosis in A549 cells, as well as caused DNA fragmentations, morphological changes and ROS generation by the mechanism studies. Furthermore, compound 17a suppression of Bcl-2 levels (decrease in the expression of the anti-apoptotic proteins Bcl-2 and down-regulation in the expression levels of Bcl-2) in A549 cells were observed, along with activation caspase-3 and PARP, which indicated that compound 17a induced A549 cells apoptosis in vitro through the ROS-mediated apoptotic pathway. These results might be useful for bromophenol derivatives to be explored and developed as novel anticancer drugs. Full article
(This article belongs to the Special Issue Synthesis of Marine-Derived Compounds)
Figures

Open AccessArticle Marine Inspired 2-(5-Halo-1H-indol-3-yl)-N,N-dimethylethanamines as Modulators of Serotonin Receptors: An Example Illustrating the Power of Bromine as Part of the Uniquely Marine Chemical Space
Mar. Drugs 2017, 15(8), 248; doi:10.3390/md15080248
Received: 21 June 2017 / Revised: 28 July 2017 / Accepted: 31 July 2017 / Published: 9 August 2017
PDF Full-text (2745 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
In previous studies, we have isolated several marine indole alkaloids and evaluated them in the forced swim test (FST) and locomotor activity test, revealing their potential as antidepressant and sedative drug leads. Amongst the reported metabolites to display such activities was 5-bromo-N
[...] Read more.
In previous studies, we have isolated several marine indole alkaloids and evaluated them in the forced swim test (FST) and locomotor activity test, revealing their potential as antidepressant and sedative drug leads. Amongst the reported metabolites to display such activities was 5-bromo-N,N-dimethyltryptamine. Owing to the importance of the judicious introduction of halogens into drug candidates, we synthesized two series built on a 2-(1H-indol-3-yl)-N,N-dimethylethanamine scaffold with different halogen substitutions. The synthesized compounds were evaluated for their in vitro and in vivo antidepressant and sedative activities using the mouse forced swim and locomotor activity tests. Receptor binding studies of these compounds to serotonin (5-HT) receptors were conducted. Amongst the prepared compounds, 2-(1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide (1a), 2-(5-bromo-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide (1d), 2-(1H-indol-3-yl)-N,N-dimethylethanamine (2a), 2-(5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine (2c), 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine (2d), and 2-(5-iodo-1H-indol-3-yl)-N,N-dimethylethanamine (2e) have been shown to possess significant antidepressant-like action, while compounds 2c, 2d, and 2e exhibited potent sedative activity. Compounds 2a, 2c, 2d, and 2e showed nanomolar affinities to serotonin receptors 5-HT1A and 5-HT7. The in vitro data indicates that the antidepressant action exerted by these compounds in vivo is mediated, at least in part, via interaction with serotonin receptors. The data presented here shows the valuable role that bromine plays in providing novel chemical space and electrostatic interactions. Bromine is ubiquitous in the marine environment and a common element of marine natural products. Full article
(This article belongs to the Special Issue Synthesis of Marine-Derived Compounds)
Figures

Back to Top